|
|
Article: The FDA Utilizes the Rosetta Syllego(TM) System to Support Management of Genome-Wide Association Study Data Submitted Through the VXDS Program.
- Article from:
- Business Wire
- Article date:
- October 2, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Rosetta Biosoftware Will Host a Webinar on the MAQC2 GWA Project, October 10, Featuring Federico Goodsaid, Ph.D., from the FDA.
SEATTLE -- Rosetta Biosoftware today announced that the U.S. Food and Drug Administration (FDA) will utilize the Rosetta Syllego[TM] system to meet its immediate need for a software solution to manage and analyze genotyping data used in genome-wide association (GWA) studies. Organizations are now beginning to submit genotyping data from GWA studies to the FDA through its Voluntary eXploratory Data Submission (VXDS) program. Research organizations conducting GWA studies have the potential to reveal genetic risk factors for diseases such as ...